Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 18/20 | 1.00 |
| ▸ | GSK3A | P49840 | 3/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 2/20 | 1.00 |
| ▸ | CLK1 | P49759 | 2/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | DYRK2 | Q92630 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CDK4 | P11802 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | CLK3 | P49761 | 1/20 | 0.67 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710734 | 1.00 | DYRK1A (1.00) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 | |
| SCHEMBL30140895 | 1.00 | DYRK1A (1.00) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 | |
| SCHEMBL19473236 | 0.91 | DYRK1A (0.84) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 | |
| SCHEMBL19473713 | 0.91 | DYRK1A (0.84) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 | |
| SCHEMBL14733473 | 0.90 | DYRK1A (1.00) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 | |
| SCHEMBL31061081 | 0.90 | DYRK1A (1.00) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 | |
| SCHEMBL19473712 | 0.90 | DYRK1A (0.82) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 | |
| SCHEMBL19473714 | 0.90 | DYRK1A (1.00) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 | |
| SCHEMBL14722895 | 0.88 | DYRK1A (1.00) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 | |
| SCHEMBL14733448 | 0.88 | DYRK1A (1.00) | DYRK1ADYRK1BGSK3AGSK3BDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | claimed |
| EP-2744797-B1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2015-09-09 | — | — | EP | claimed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | claimed |
| WO-2023140846-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | FELICITEX THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230226061-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | FELICITEX THERAPUETICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11202779-B2 | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors | FELICITEX THERAPEUTICS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20190298723-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | FELICITEX THERAPEUTICS, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190290651-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | FELICITEX THERAPEUTICS INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-10322128-B2 | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors | FELICITEX THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10314843-B2 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis | FELICITEX THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| WO-2017181087-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | FELICITEX THERAPEUTICS, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| EP-2744797-B1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2015-09-09 | — | — | EP | disclosed |
| EP-2744797-B1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| WO-2013026806-A1 | DYRK1 INHIBITORS AND USES THEREOF | EXONHIT SA (FR) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322128-B2 | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors | EGFR, ERBB2, ERBB3 | DYRK1A 552/4885DYRK1B 644/4885GSK3A 489/4885 |
| US-20190298723-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | DYRK1A 552/4885DYRK1B 644/4885GSK3A 489/4885 |
| US-20230226061-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | KRAS, BRAF, RAF1 | DYRK1A 12/4885DYRK1B 10/4885GSK3A 418/4885 |
| US-10314843-B2 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis | BUB1B, BUB1, CCNB1 | DYRK1A 999/4885DYRK1B 1125/4885GSK3A 479/4885 |
| US-11202779-B2 | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors | EGFR, ERBB2, ERBB3 | DYRK1A 552/4885DYRK1B 644/4885GSK3A 489/4885 |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | DYRK1A 1/4885DYRK1B 2/4885GSK3A 204/4885 |
| US-20190290651-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | BUB1B, BUB1, CCNB1 | DYRK1A 999/4885DYRK1B 1125/4885GSK3A 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.